Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
The British journal of psychiatry : the journal of mental science November 1, 2024 Gero Joks, Steve Su, Jarrad King
A commentary on the KADS study raises concerns about the interpretation of its findings on repeated subcutaneous ketamine injections for treatment-resistant depression. The authors of the commentary aim to clarify points to ensure accurate and balanced information is presented to healthcare professionals, questioning the researchers' discussion of efficacy and safety results from the 4-week randomized double-blind active-controlled trial.